Literature DB >> 10160476

Is there scope for improving the cost-effective prescribing of nonsteroidal anti-inflammatory drugs?

K Bloor1, A Maynard.   

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) are used widely throughout the world to relieve the symptoms of musculoskeletal disorders, in particular osteoarthritis and rheumatoid arthritis. These drugs have significant adverse effects, including gastrointestinal ulceration and the associated complications of perforation and bleeding. The relative toxicity of competing forms of branded and generic NSAIDs varies considerably. Their acquisition cost also varies considerably, sometimes with relatively more toxic drugs being more expensive. Thus, it may be possible to reduce both adverse effects and pharmaceutical expenditures associated with NSAIDs, if doctors' prescribing behaviour can be changed. A tentative exploration of alternative patterns of NSAID use demonstrates that it may be possible to reduce expenditures on NSAIDs in the UK to below the 1994 level, and reduce adverse events. If prescribing of NSAIDs was reduced by 25%, average dosage reduced by 10% and patients switched to less toxic NSAIDs, up to 86 million pounds sterling could be saved per year in the UK, the number of serious adverse events per year reduced by 189 (from a baseline figure of around 500) and the annual number of gastrointestinal complications reduced by 127 (from a baseline figure of around 315). Such results may be achieved without reductions in the quality of life of patients using these drugs. The available clinical and economic information about NSAIDs is limited, and the publication of numerous poor quality studies has corrupted the knowledge base. Despite these problems, there appears to be enough evidence to indicate that expenditure on NSAIDs could be considerably reduced and significant adverse effects could be avoided if general practitioners were persuaded to change their prescribing behaviour. Inefficient and inappropriate prescribing of these often beneficial, but sometimes dangerous, drugs appears to be wasting scarce UK National Health Service resources and harming patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 10160476     DOI: 10.2165/00019053-199609060-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  29 in total

1.  Principles of educational outreach ('academic detailing') to improve clinical decision making.

Authors:  S B Soumerai; J Avorn
Journal:  JAMA       Date:  1990-01-26       Impact factor: 56.272

2.  The journal's policy on cost-effectiveness analyses.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

3.  Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial.

Authors:  D Y Graham; N M Agrawal; S H Roth
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

4.  Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis.

Authors:  P C Gøtzsche
Journal:  Control Clin Trials       Date:  1989-03

5.  Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.

Authors:  J D Bradley; K D Brandt; B P Katz; L A Kalasinski; S I Ryan
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

6.  A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis.

Authors:  P A Rochon; J H Gurwitz; R W Simms; P R Fortin; D T Felson; K L Minaker; T C Chalmers
Journal:  Arch Intern Med       Date:  1994-01-24

7.  Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.

Authors:  L A García Rodríguez; H Jick
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

8.  Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected?

Authors:  P A Dieppe; S J Frankel; B Toth
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

9.  Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group.

Authors:  D Y Graham; R H White; L W Moreland; T T Schubert; R Katz; R Jaszewski; E Tindall; G Triadafilopoulos; S C Stromatt; L S Teoh
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

10.  Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine.

Authors:  R S Ehsanullah; M C Page; G Tildesley; J R Wood
Journal:  BMJ       Date:  1988-10-22
View more
  7 in total

Review 1.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 2.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

3.  Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK.

Authors:  C J McCabe; R L Akehurst; J Kirsch; M Whitfield; M Backhouse; A D Woolf; D L Scott; P Emery; I Haslock
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

4.  Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.

Authors:  Nicholas Latimer; Joanne Lord; Robert L Grant; Rachel O'Mahony; John Dickson; Philip G Conaghan
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

Review 5.  A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.

Authors:  T A Burke; R A Zabinski; D Pettitt; N Maniadakis; C J Maurath; J L Goldstein
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Assessing the economic impact of adverse drug effects.

Authors:  Rosa Rodríguez-Monguió; María José Otero; Joan Rovira
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Authors:  Nicholas Latimer; Joanne Lord; Robert L Grant; Rachel O'Mahony; John Dickson; Philip G Conaghan
Journal:  BMJ       Date:  2009-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.